Preliminary results showed that responders had lower tumor burden at baseline, higher CD8+ lymphocyte count, and higher Effector : Target ratio, however there was no correlation between CD33 expression on AML blasts at baseline and response (12, 31). This evidence concerns the gene CD8A and neoplasm.